0001493152-23-013783.txt : 20230427 0001493152-23-013783.hdr.sgml : 20230427 20230427091720 ACCESSION NUMBER: 0001493152-23-013783 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230427 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Changes in Control of Registrant ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230427 DATE AS OF CHANGE: 20230427 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Provention Bio, Inc. CENTRAL INDEX KEY: 0001695357 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38552 FILM NUMBER: 23852284 BUSINESS ADDRESS: STREET 1: 55 BROAD STREET, 2ND FLOOR CITY: RED BANK STATE: NJ ZIP: 07701 BUSINESS PHONE: 908-428-9136 MAIL ADDRESS: STREET 1: 55 BROAD STREET, 2ND FLOOR CITY: RED BANK STATE: NJ ZIP: 07701 FORMER COMPANY: FORMER CONFORMED NAME: Provention Inc. DATE OF NAME CHANGE: 20170120 8-K 1 form8-k.htm
0001695357 false --12-31 0001695357 2023-04-27 2023-04-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): April 27, 2023

 

Provention Bio, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-38552   81-5245912
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

55 Broad Street, 2nd Floor

Red Bank, NJ

 

07701

(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (908) 336-0360

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.0001 par value per share   PRVB   The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

INTRODUCTORY NOTE

 

As previously disclosed in the Current Report on Form 8-K filed on March 13, 2023 with the Securities and Exchange Commission (the “SEC”) by Provention Bio, Inc., a Delaware corporation (the “Company”), on March 12, 2023, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), with Sanofi S.A., a French société anonyme (“Parent”), and Parent’s indirect wholly-owned subsidiary, Zest Acquisition Sub, Inc., a Delaware corporation (“Purchaser”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on March 24, 2023, Purchaser commenced a tender offer (the “Offer”) to purchase all of the issued and outstanding shares (the “Shares”) of common stock, par value $0.0001 per share, of the Company at a price of $25.00 per Share, to the seller in cash, without interest, but subject to any applicable withholding of taxes (the “Offer Price”) upon the terms and subject to the conditions set forth in the Offer to Purchase, dated March 24, 2023, and in the related Letter of Transmittal.

 

The Offer, as extended, expired one minute after 11:59 p.m. Eastern Time, on April 26, 2023 (the “Expiration Time”). The depositary for the Offer advised that, as of the Expiration Time, a total of 74,490,556 Shares were validly tendered and “received” (as defined in Section 251(h) of the General Corporation Law of the State of Delaware (the “DGCL”)) by the depository and not validly withdrawn pursuant to the Offer, representing approximately 73.065% of outstanding Shares as of such time. Accordingly, the Minimum Tender Condition (as defined in the Merger Agreement) has been satisfied. Each condition to the Offer having been satisfied or waived, Purchaser irrevocably accepted for payment all Shares that were validly tendered and not validly withdrawn on April 27, 2023. Parent and Purchaser are required to make prompt payment for such Shares.

 

On April 27, 2023, following consummation of the Offer, Purchaser merged with and into the Company (the “Merger”), with the Company as the surviving corporation. The Merger was completed pursuant to Sections 251(c) and 251(h) of the DGCL.

 

Item 1.02Termination of a Material Definitive Agreement.

 

In connection with the closing of the Merger, on April 27, 2023, the Company fully prepaid all loans outstanding pursuant to the Loan and Security Agreement, dated as of August 31, 2022 (as amended by that certain First Amendment to Loan and Security Agreement, dated as of February 2, 2023, the “Loan Agreement”), by and among the Company, certain financial institutions party thereto and Hercules Capital, Inc. and terminated the Loan Agreement.

 

Item 2.01Completion of Acquisition or Disposition of Assets.

 

At the effective time of the Merger (the “Effective Time”), each issued and outstanding Share (other than (i) Shares held in the treasury of the Company or owned by the Company or any direct or indirect wholly owned subsidiary of the Company immediately prior to the Effective Time, (ii) Shares owned by Parent or any direct or indirect wholly owned subsidiary of Parent (other than Purchaser) immediately prior to the Effective Time, (iii) Shares irrevocably accepted for purchase in the Offer and (iv) Shares outstanding immediately prior to the Effective Time and held by stockholders who are entitled to demand, and properly demanded, appraisal for such Shares in accordance with Section 262 of the DGCL) was cancelled and converted into the right to receive an amount in cash equal to the Offer Price, without interest, less applicable withholding of taxes.

 

In addition, at the Effective Time, each option to purchase Shares granted under the Company’s 2017 Equity Incentive Plan (as amended and restated) (the “2017 Plan”) and the Company’s 2020 Inducement Plan (as amended) (each such option, a “Company Stock Option”) that was outstanding and vested immediately prior to the Effective Time, was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.

 

2
 

 

Further, each Company Stock Option that was outstanding and unvested immediately prior to the Effective Time, whether or not then subject to any performance or other vesting condition, vested in full immediately prior to the Effective Time, with any performance condition deemed achieved in full, and as of the Effective Time, each such Company Stock Option was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.

 

Also at the Effective Time, each (i) warrant to purchase Shares issued by the Company to MDB and certain of MDB’s designees on July 3, 2018 (the “IPO Warrants”) and (ii) warrant to purchase Shares issued by the Company pursuant to those certain Warrant Agreements, dated as of September 15, 2022 and February 2, 2023, by and between the Company and Hercules Capital, Inc. (the “Term Loan Warrants,” and together with the IPO Warrants, the “Company Warrants”) that was outstanding immediately prior to the Effective Time was, with respect to the Term Loan Warrants, cancelled, and, with respect to the IPO Warrants, deemed exercised, and, in exchange therefor, the holder of such former Company Warrant became entitled to receive (without interest), an amount of cash equal to the product of (x) the total number of Shares into which the Company Warrant was exercisable as of immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Warrant.

 

The foregoing summary of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Merger Agreement attached as Exhibit 2.1 to the Current Report on Form 8-K filed with the SEC by the Company on March 13, 2023 and incorporated herein by reference.

 

Item 3.01Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

In connection with the consummation of the Merger, on April 26, 2023, the Company (i) notified The Nasdaq Stock Market LLC (“Nasdaq”) of the consummation of the Merger and (ii) requested that Nasdaq (x) halt trading of the Shares effective as of the evening of April 26, 2023 after market close and suspend trading in the Shares prior to market open on the morning of April 27, 2023, and (y) file with the SEC a Notification of Removal from Listing and/or Registration on Form 25 to effect the delisting of all Shares from Nasdaq and the deregistration of such Shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company intends to file with the SEC a Certification and Notice of Termination of Registration on Form 15 under the Exchange Act, requesting that the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act be suspended.

 

Item 3.03Material Modification to Rights of Security Holders.

 

The information contained in the Introductory Note and in Items 2.01, 3.01, 5.01 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.

 

At the Effective Time, holders of Shares immediately prior to such time ceased to have any rights as stockholders of the Company (other than their right to receive the Offer Price for each Share held, pursuant to the Merger Agreement).

 

3
 

 

Item 5.01Changes in Control of Registrant.

 

At the Effective Time, the Company became a wholly-owned subsidiary of Parent.

 

The information contained in the Introductory Note and in Items 2.01, 5.02 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01.

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Directors

 

In accordance with the Merger Agreement, at the Effective Time, each of the directors of the Company (Ashleigh Palmer; Avery Catlin; Rita Jain; John Jenkins; Wayne Pisano; and Nancy Wysenski) resigned from his or her respective position as a member of the Company’s board of directors, and any committee thereof. These resignations were in connection with the Merger and not as a result of any disagreements between the Company and the resigning individuals on any matters related to the Company’s operations, policies or practices.

 

As of the Effective Time, in accordance with the Merger Agreement, Michael Tolpa, the sole director of Purchaser immediately prior to the Effective Time, became the sole director of the Company as the surviving corporation. After the Effective Time, Aventis, Inc., as the sole stockholder of the Company (“Aventis”), passed resolutions appointing Olivier Bogillot and Debora C. Pellicano as the sole directors of the Company.

 

Officers

 

As of the Effective Time, in accordance with the Merger Agreement, Michael Tolpa, the President and sole officer of Purchaser immediately prior to the Effective Time became the President and sole officer of the Company as the surviving corporation. After the Effective Time but before Aventis passed the resolutions described above, Michael Tolpa, as the sole director of the Company, passed resolutions appointing (or confirming the continued appointment of) the following individuals as officers of the Company: (i) Olivier Bogillot, President, (ii) Debora Pellicano, Vice President, Chief Financial Officer, (iii) Francisco Leon, Chief Scientific Officer, (iv) Eleanor L. Ramos, Chief Medical Officer, (v) Jason Hoitt, Chief Commercial Officer, (vi) Benedict Osorio, Chief Quality Officer, (vii) Christina Yi, Chief Operations Officer, (viii) Jamie Haney, Secretary, (ix) Stacy Apgar, Assistant Secretary and (x) Michael Tolpa, Treasurer.

 

Item 5.03Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

Pursuant to the terms of the Merger Agreement, as of the Effective Time, the Company’s second amended and restated certificate of incorporation was amended and restated in its entirety, and the Company’s amended and restated bylaws were amended and restated in their entirety. Copies of the third amended and restated certificate of incorporation and second amended and restated bylaws are filed as Exhibits 3.1 and 3.2, respectively, and are incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description of Exhibit
2.1*   Agreement and Plan of Merger, dated as of March 12, 2023, among the Company, Parent and Purchaser (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on March 13, 2023).
3.1   Third Amended and Restated Certificate of Incorporation (filed herewith).
3.2   Second Amended and Restated Bylaws (filed herewith).
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

*Certain exhibits and the schedules to the Agreement and Plan of Merger have been omitted from this filing pursuant to Item 601(b)(2)(ii) of Regulation S-K. Pursuant to Item 601(a)(5) of Regulation S-K, the Company hereby agrees to supplementally furnish to the SEC upon request any omitted schedule or exhibit to the Agreement and Plan of Merger.

 

4
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Provention Bio, Inc.
    
  By: /s/ Michael Tolpa
  Name: Michael Tolpa
  Title: Treasurer

 

Dated: April 27, 2023

 

5

 

EX-3.1 2 ex3-1.htm

 

Exhibit 3.1

 

THIRD AMENDED AND RESTATED

 

CERTIFICATE OF INCORPORATION OF

 

PROVENTION BIO, INC.

 

FIRST: The name of the corporation is: Provention Bio, Inc.

 

SECOND: The address of the registered office of the Corporation in the State of Delaware is: 251 Little Falls Drive, in the City of Wilmington, County of New Castle, 19808. The name of its registered agent for service of process in the State of Delaware at such address is Corporation Service Company.

 

THIRD: The purpose of the Corporation is to engage in any and all lawful acts or activities for which corporations may be organized under the DGCL.

 

FOURTH: The total number of shares of capital stock which the Corporation shall have authority to issue is 103,000,000, all of which shares shall be common stock each having a par value of $0.0001 per share.

 

FIFTH: In addition to the powers and authority herein before or by statute expressly conferred upon them, the board of directors of the Corporation (the “Board of Directors”) is hereby empowered to exercise all such powers and do all such acts and things as may be exercised or done by the Corporation, subject to the provisions of the DGCL, this Third Amended and Restated Certificate of Incorporation and the bylaws of the Corporation.

 

SIXTH: In furtherance and not in limitation of the powers conferred by law, subject to any limitations contained in this Third Amended and Restated Certificate of Incorporation, the bylaws of the Corporation may be adopted, amended or repealed by a majority of the Board of Directors, but any bylaws adopted by the Board of Directors may be amended or repealed by the stockholders entitled to vote thereon. Election of directors need not be by written ballot unless the bylaws of the Corporation so provide.

 

SEVENTH: The Corporation shall provide indemnification as follows:

 

1. To the maximum extent permitted by the DGCL, as the same exists or may hereafter be amended from time to time, a director or officer of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or otherwise. If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. Notwithstanding the foregoing, a director or officer shall be liable to the extent provided by applicable law (i) for any breach of the director’s or officer’s duty of loyalty to the Corporation or its stockholders, (ii) for acts or omissions of the director or officer not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL with respect to directors, (iv) for any transaction from which the director or officer derived any improper personal benefit or (v) for any action by or in right of the Corporation, in the case of officers only. Neither any amendment nor repeal of this Article SEVENTH, nor the adoption of any provision of this Third Amended and Restated Certificate of Incorporation inconsistent with this Article SEVENTH, shall eliminate or reduce the effect of this Article SEVENTH in respect of any matter occurring, or any cause of action, suit or proceeding accruing or arising or that, but for this Article SEVENTH, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision.

 

 
 

 

2. To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which the DGCL permits the Corporation to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section 145 of the DGCL. Any amendment, repeal or modification of the foregoing provisions of this Article SEVENTH shall not adversely affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal or modification.

 

EIGHTH: Meetings of stockholders may be held within or without the State of Delaware, as the bylaws may provide. The books of the Corporation may be kept (subject to any provision contained in the DGCL) outside the State of Delaware at such place or places as may be designated from time to time by the Board of Directors or in the bylaws of the Corporation.

 

NINTH: The Board of Directors reserves the right to amend, alter, change or repeal any provision contained in this Third Amended and Restated Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon stockholders herein are granted subject to this reservation.

 

[The remainder of this page is intentionally left blank.]

 

-2-

 

EX-3.2 3 ex3-2.htm

 

Exhibit 3.2

 

SECOND AMENDED AND RESTATED BYLAWS

OF

PROVENTION BIO, INC.

 

(a Delaware corporation)

 

Article I

 

Stockholders

 

Section 1. Annual Meetings. The annual meeting of the stockholders of Provention Bio, Inc. (the “Corporation”) for the election of directors and for the transaction of such other business as may properly come before the meeting shall be held each year at such date and time, within or without the State of Delaware, as the board of directors of the Corporation (the “Board of Directors”) shall determine.

 

Section 2. Special Meetings. Special meetings of stockholders for the transaction of such business as may properly come before the meeting or for any other purpose or purposes may be called by order of the Board of Directors or by stockholders holding together at least a majority of all the shares of the Corporation entitled to vote at the meeting, and shall be held at such date and time, within or without the State of Delaware, as may be specified by such order. Whenever the directors shall fail to fix such place, the meeting shall be held at the principal executive office of the Corporation.

 

Section 3. Notice of Meetings. Written notice of all meetings of the stockholders, stating the place (if any), date and hour of the meeting, the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and the place within the city or other municipality or community at which the list of stockholders may be examined, shall be mailed or delivered (physically or electronically) to each stockholder entitled to notice of or to vote at such meeting not less than 10 nor more than 60 days prior to the meeting. Notice of any special meeting shall state in general terms the purpose or purposes for which the meeting is to be held, and at such special meeting, only such business shall be conducted as shall be specified in the notice of meeting. Stockholders may participate in any such meeting by means of a conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in meeting shall constitute presence at such meeting. Without limiting the manner by which notice otherwise may be given effectively to stockholders, notice of meetings may be given to stockholders by means of electronic transmission in accordance with applicable law. Notice of any meeting need not be given to any stockholder who shall, either before or after the meeting, submit a waiver of notice or who shall attend such meeting, except when the stockholder attends for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of the meeting shall be bound by the proceedings of the meeting in all respects as if due notice thereof had been given.

 

 
 

 

Section 4. Stockholder Lists. The officer who has charge of the stock ledger of the Corporation shall prepare and make, at least 10 days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number and class of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not so specified, at the place where the meeting is to be held. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present.

 

The stock ledger shall be the only evidence as to who are the stockholders entitled to examine the stock ledger, the list required by this section or the books of the Corporation, or to vote in person or by proxy at any meeting of stockholders.

 

Section 5. Quorum. Except as otherwise provided by law or the Corporation’s Certificate of Incorporation, a quorum for the transaction of business at any meeting of stockholders shall consist of the holders of record of a majority of the issued and outstanding shares of the capital stock of the Corporation entitled to vote at the meeting, present in person or by proxy. At all meetings of the stockholders at which a quorum is present, all matters, except as otherwise provided by law or the Certificate of Incorporation, shall be decided by the vote of the holders of a majority of the shares entitled to vote thereat present in person or by proxy. If there be no such quorum, the holders of a majority of such shares so present or represented may adjourn the meeting from time to time, without further notice, until a quorum shall have been obtained. When a quorum is once present it is not broken by the subsequent withdrawal of any stockholder.

 

Section 6. Organization. Meetings of stockholders shall be presided over by the Chairman, if any, or if none or in the Chairman’s absence the Vice-Chairman, if any, or if none or in the Vice-Chairman’s absence, the President, if any, or if none or in the President’s absence a Vice-President, or, if none of the foregoing is present, by a chairman to be chosen by the stockholders entitled to vote who are present in person or by proxy at the meeting. The Secretary of the Corporation, or in the Secretary’s absence, the presiding officer of the meeting shall appoint any person present to act as secretary of the meeting.

 

Section 7. Voting; Proxies; Required Vote.

 

(a) At each meeting of stockholders, every stockholder entitled to vote at such meeting shall be entitled to vote in person or by proxy appointed by instrument in writing, subscribed by such stockholder or by such stockholder’s duly authorized attorney-in-fact (but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period), and, unless the Certificate of Incorporation provides otherwise, shall have one vote for each share of stock entitled to vote registered in the name of such stockholder on the books of the Corporation on the applicable record date fixed pursuant to these Bylaws. At all elections of directors the voting may but need not be by ballot and a plurality of the votes cast there shall elect such directors. Except as otherwise required by law or the Certificate of Incorporation, any other action shall be authorized by the vote of the majority of the shares present in person or by proxy at the meeting and entitled to vote on the subject matter.

 

2
 

 

(b) Any action required or permitted to be taken at any meeting of stockholders may, except as otherwise required by law or the Certificate of Incorporation, be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, shall be signed by the holders of record of the issued and outstanding capital stock of the Corporation having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted, and the writing or writings are filed with the permanent records of the Corporation. Prompt notice of the taking of corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing.

 

Section 8. Inspectors. The Board of Directors, in advance of any meeting, may, but need not, appoint one or more inspectors of election to act at the meeting or any adjournment thereof. If an inspector or inspectors are not so appointed, the person presiding at the meeting may, but need not, appoint one or more inspectors. In case any person who may be appointed as an inspector fails to appear or act, the vacancy may be filled by an appointment made by the directors in advance of the meeting or at the meeting by the person presiding thereat. Each inspector, if any, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector at such meeting with strict impartiality and according to the best of his or her ability. The inspectors, if any, shall determine the number of shares of stock outstanding and the voting power of each, the shares of stock represented at the meeting, the existence of a quorum, and the validity and effect of proxies, and shall receive votes, ballots or consents, hear and determine all challenges and questions arising in connection with the right to vote, count and tabulate all votes, ballots or consents, determine the result, and do such acts as are proper to conduct the election or vote with fairness to all stockholders. On request of the person presiding at the meeting, the inspector or inspectors, if any, shall make a report in writing of any challenge, question or matter determined by such inspector or inspectors and execute a certificate of any fact found by such inspector or inspectors.

 

Section 9. Written Consent of Stockholders Without a Meeting. Any action to be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action to be so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered (physically or electronically) to the Corporation by delivery to its registered office in the State of Delaware, its principal place of business, or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall, to the extent required by applicable law, be given to those stockholders who have not consented in writing, and who, if the action had been taken at a meeting, would have been entitled to notice of the meeting if the record date for notice of such meeting had been the date that written consents signed by a sufficient number of holders to take the action were delivered to the Corporation.

 

Section 10. Remote Communication. Stockholders and proxy holders not physically present at a meeting of stockholders may, by means of remote communication: (i) participate in a meeting of stockholders; and (ii) be deemed present in person and vote at a meeting of stockholders, whether such meeting is to be held at a designated place or solely by means of remote communication, provided that (A) the Corporation shall implement reasonable measures to verify that each person deemed present and permitted to vote at the meeting by means of remote communication is a stockholder or proxyholder, (B) the Corporation shall implement reasonable measures to provide such stockholders and proxy holders a reasonable opportunity to participate in the meeting and to vote on matters submitted to the stockholders, including an opportunity to read or hear the proceedings of the meeting substantially concurrently with such proceedings, and (C) if any stockholder or proxy holder votes or takes other action at the meeting by means of remote communication, a record of such votes or other action shall be maintained by the Corporation.

 

3
 

 

Article II

 

Board of Directors

 

Section 1. General Powers. The business, property and affairs of the Corporation shall be managed by, or under the direction of, the Board of Directors.

 

Section 2. Qualification; Number; Term; Compensation.

 

(a) Each director shall be at least 18 years of age. A director need not be a stockholder, a citizen of the United States or a resident of the State of Delaware. The number of directors constituting the entire Board of Directors shall be fixed initially by the incorporator and thereafter by the Board of Directors and shall be at least one, or such larger number as may be fixed initially by the incorporator and thereafter from time to time by the Board of Directors, one of whom may be selected by the Board of Directors to be its Chairman. The use of the phrase “entire Board of Directors” herein refers to the total number of directors which the Corporation would have if there were no vacancies.

 

(b) Directors who are elected at an annual meeting of stockholders, and directors who are elected in the interim to fill vacancies and newly created directorships, shall hold office until the next annual meeting of stockholders and until their successors are elected and qualified or until their earlier resignation or removal.

 

(c) Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, the Board of Directors shall have the authority to fix the compensation of directors. The directors may be paid their expenses, if any, of attendance at each meeting of the Board of Directors and may be paid a fixed sum for attendance at each meeting of the Board of Directors or a stated salary as director. No such payment shall preclude any director from serving the Corporation in any other capacity and receiving compensation therefor. Members of special or standing committees may be allowed like compensation for attending committee meetings.

 

Section 3. Quorum and Manner of Voting. Except as otherwise provided by law, a majority of the entire Board of Directors shall constitute a quorum. A majority of the directors present, whether or not a quorum is present, may adjourn a meeting from time to time to another time and place without notice. The vote of the majority of the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors. Each director shall be entitled to one vote on exactly the matter presented to the Board of Directors for approval.

 

4
 

 

Section 4. Places of Meetings. Meetings of the Board of Directors may be held at any place within or without the State of Delaware, as may from time to time be fixed by resolution of the Board of Directors, or as may be specified in the notice of meeting, if any.

 

Section 5. Annual Meeting. Following the annual meeting of stockholders, the newly elected Board of Directors shall meet for the purpose of the election of officers and the transaction of such other business as may properly come before the meeting. Such meeting may be held without notice immediately after the annual meeting of stockholders at the same place at which such stockholders’ meeting is held.

 

Section 6. Regular Meetings. Regular meetings of the Board of Directors shall be held at such times and places as the Board of Directors shall from time to time determine by resolution. Notice need not be given of regular meetings of the Board of Directors held at times and places fixed by resolution of the Board of Directors and promptly communicated to all directors then in office.

 

Section 7. Special Meetings. Special meetings of the Board of Directors shall be held whenever called by the Chairman, the President or by a majority of the directors then in office.

 

Section 8. Notice of Meetings. Whenever required, notice of the place, date and time and the purpose or purposes of each meeting of the Board of Directors shall be given to each director not less than two calendar days before the day of the meeting by mail, telephone, facsimile, e-mail, or by personal delivery.

 

Section 9. Meetings by Means of Conference Telephone. Unless otherwise provided by the Certificate of Incorporation or these Bylaws, members of the Board of Directors, or any committee designated by the Board of Directors, may participate in a meeting of the Board of Directors or such committee by means of a conference telephone or similar communication equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting pursuant to this Section 9 shall constitute presence at such meeting.

 

Section 10. Organization. The Chairman, if there be one, or if none or in the Chairman’s absence or inability to act the Vice Chairman, if any, or if none or in the Vice-Chairman’s absence or inability to act the President, or in the President’s absence or inability to act any Vice-President who is a member of the Board of Directors, or in such Vice-President’s absence or inability to act, a chairman chosen by the directors, shall preside at all meetings of the Board of Directors and shall have such other powers and duties as may from time to time be assigned by the Board of Directors. The Secretary of the Corporation shall act as secretary at all meetings of the Board of Directors when present, and, in the Secretary’s absence, the presiding officer may appoint any person to act as secretary.

 

Section 11. Resignation; Removal. Any director may resign at any time upon written notice to the Corporation and such resignation shall take effect upon receipt thereof by the President or Secretary, unless otherwise specified in the resignation. Any or all of the directors may be removed, with or without cause, by the holders of a majority of the shares of stock outstanding and entitled to vote for the election of directors.

 

5
 

 

Section 12. Vacancies. Unless otherwise provided in these Bylaws, vacancies on the Board of Directors, whether caused by resignation, death, disqualification, removal, an increase in the authorized number of directors or otherwise, may be filled by the affirmative vote of a majority of the remaining directors, although less than a quorum, or by a sole remaining director, or at a special meeting of the stockholders, by the holders of shares entitled to vote for the election of directors.

 

Section 13. Action by Written Consent. Any action required or permitted to be taken at any meeting of the Board of Directors may be taken without a meeting if all the directors consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the Board of Directors.

 

Article III

 

Committees

 

Section 1. Appointment. From time to time the Board of Directors by a resolution adopted by a majority of the entire Board of Directors may appoint any committee or committees for any purpose or purposes, to the extent lawful, which shall have powers as shall be determined and specified by the Board of Directors in the resolution of appointment.

 

Section 2. Procedures, Quorum and Manner of Acting. Each committee shall fix its own rules of procedure, and shall meet where and as provided by such rules or by resolution of the Board of Directors. Except as otherwise provided by law, the presence of a majority of the then appointed members of a committee shall constitute a quorum for the transaction of business by that committee, and in every case where a quorum is present the affirmative vote of a majority of the members of the committee present shall be the act of the committee. Each committee shall keep minutes of its proceedings, and actions taken by a committee shall be reported to the Board of Directors.

 

Section 3. Action by Written Consent. Any action required or permitted to be taken at any meeting of any committee of the Board of Directors may be taken without a meeting if all the members of the committee consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the committee.

 

Section 4. Term; Termination. In the event any person shall cease to be a director of the Corporation, such person shall simultaneously therewith cease to be a member of any committee appointed by the Board of Directors.

 

Article IV

 

Officers

 

Section 1. Election and Qualifications. The Board of Directors shall elect the officers of the Corporation, which shall include a President and a Secretary, and may include, by election or appointment, one or more Vice-Presidents (any one or more of whom may be given an additional designation of rank or function), a Treasurer and such Assistant Secretaries, such Assistant Treasurers and such other officers as the Board of Directors may from time to time deem proper. Each officer shall have such powers and duties as may be prescribed by these Bylaws and as may be assigned by the Board of Directors or the President. Any two or more offices may be held by the same person. The Chairman of the Board of Directors, if one is appointed, shall, if present, preside at all meetings of the stockholders.

 

6
 

 

Section 2. Term of Office and Remuneration. All officers shall hold office until their successors are elected and qualified. Any vacancy in any office arising from any cause may be filled for the unexpired portion of the term by the Board of Directors. The remuneration of all officers of the Corporation may be fixed by the Board of Directors or in such manner as the Board of Directors shall provide.

 

Section 3. Resignation; Removal. Any officer may resign at any time upon written notice to the Corporation and such resignation shall take effect upon receipt thereof by the President or Secretary, unless otherwise specified in the resignation. Any officer shall be subject to removal, with or without cause, at any time by vote of a majority of the entire Board of Directors.

 

Section 4. President. The President shall, subject to control of the Board of Directors, have direction and control of the business and officers of the Corporation, shall have the general powers and duties of management usually vested in the president of a corporation, and shall have such other powers and duties as may from time to time be assigned by the Board of Directors. The President may appoint and remove assistant officers and other agents and employees; and may execute and deliver in the name of the Corporation powers of attorney, contracts, bonds and other obligations and instruments.

 

Section 5. Vice-President. A Vice-President may execute and deliver in the name of the Corporation contracts and other obligations and instruments pertaining to the regular course of the duties of said office, and shall have such other authority as from time to time may be assigned by the Board of Directors.

 

Section 6. Treasurer. The Treasurer (if any) shall in general have all duties incident to the position of Treasurer and such other duties as may be assigned by the Board of Directors.

 

Section 7. Secretary. The Secretary shall in general have all the duties incident to the office of Secretary and such other duties as may be assigned by the Board of Directors.

 

Section 8. Other Officers. Such other officers as the Board of Directors may choose shall perform such duties and have such powers as from time to time may be assigned to them by the Board of Directors. The Board of Directors may delegate to any other officer of the Corporation the power to choose such other officers and to prescribe their respective duties and powers.

 

7
 

 

Article V

 

Books and Records

 

Section 1. Location. The books and records of the Corporation may be kept at such place or places within or outside the State of Delaware as the Board of Directors or the respective officers in charge thereof may from time to time determine. The record books containing the names and addresses of all stockholders, the number and class of shares of stock held by each and the dates when they respectively became the owners of record thereof shall be kept by the Secretary as prescribed in these Bylaws and by such officer or agent as shall be designated by the Board of Directors.

 

Section 2. Addresses of Stockholders. Notices of meetings and all other corporate notices may be delivered personally, electronically or mailed to each stockholder at the stockholder’s address as it appears on the records of the Corporation.

 

Section 3. Fixing Date for Determination of Stockholders of Record.

 

(a) In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors and which record date shall not be more than 60 nor less than 10 days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.

 

(b) In order that the Corporation may determine the stockholders entitled to consent to corporate action in writing without a meeting, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors and if no record date has been fixed by the Board of Directors, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting, when no prior action by the Board of Directors is required, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Corporation by delivery to its registered office in this State, its principal place of business, or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the Corporation’s registered office shall be by hand or by certified or registered mail, return receipt requested. If no record date has been fixed by the Board of Directors and prior action by the Board of Directors is required by this article, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action.

 

(c) In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted and if no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.

 

8
 

 

Article VI

 

Certificates Representing Stock

 

Section 1. Certificates; Signatures. The shares of the Corporation’s stock may be certificated or uncertificated, as provided under the Delaware General Corporation Law, as it may be amended and supplemented from time to time (the “DGCL”), and shall be entered in the books of the Corporation and registered as they are issued. Any certificates representing shares of stock shall be in such form as shall be approved by the Board of Directors. Every holder of stock represented by certificates and upon request every holder of uncertificated shares shall be entitled to have a certificate, signed by or in the name of the Corporation by the Chairman or Vice-Chairman of the Board of Directors, or the President or Vice-President, and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary of the Corporation, representing the number of shares registered in certificate form. Any and all signatures on any such certificate may be facsimiles. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer, transfer agent or registrar at the date of issue. The name of the holder of record of the shares represented thereby, with the number of such shares and the date of issue, shall be entered on the books of the Corporation.

 

Section 2. Transfers of Stock. Upon compliance with provisions restricting the transfer or registration of transfer of shares of stock, if any, shares of capital stock shall be transferable on the books of the Corporation only by the holder of record thereof in person, or by a duly authorized attorney, upon surrender and cancellation of certificates for a like number of shares, properly endorsed, and the payment of all taxes due thereon.

 

Section 3. Fractional Shares. The Corporation may, but shall not be required to, issue certificates for fractions of a share where necessary to effect authorized transactions, or the Corporation may pay in cash the fair value of fractions of a share as of the time when those entitled to receive such fractions are determined, or it may issue scrip in registered or bearer form over the manual or facsimile signature of an officer of the Corporation or of its agent, exchangeable as therein provided for full shares, but such scrip shall not entitle the holder to any rights of a stockholder except as therein provided.

 

Section 4. Rules and Regulations. The Board of Directors shall have power and authority to make all such rules and regulations as it may deem expedient concerning the issue, transfer and registration of certificates representing shares of the Corporation.

 

Section 5. Lost, Stolen or Destroyed Certificates. The Corporation may issue a new certificate of stock in place of any certificate, theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Board of Directors may require the owner of any lost, stolen or destroyed certificate, or his legal representative, to give the Corporation a bond sufficient to indemnify the Corporation against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of any such new certificate.

 

9
 

 

Article VII

 

Dividends

 

Subject always to applicable law and the Certificate of Incorporation, the Board of Directors shall have full power to determine whether any, and, if any, what part of any, funds legally available for the payment of dividends shall be declared as dividends and paid to stockholders; the division of the whole or any part of such funds of the Corporation shall rest wholly within the lawful discretion of the Board of Directors, and it shall not be required at any time, against such discretion, to divide or pay any part of such funds among or to the stockholders as dividends or otherwise; and before payment of any dividend, there may be set aside out of any funds of the Corporation available for dividends such sum or sums as the Board of Directors from time to time, in its absolute discretion, deems proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the Corporation, or for such other purpose as the Board of Directors shall think conducive to the interest of the Corporation, and the Board of Directors may modify or abolish any such reserve in the manner in which it was created. Subject to applicable law and the Certificate of Incorporation, dividends upon the shares of capital stock of the Corporation may be declared by the Board of Directors at any regular or special meeting of the Board of Directors. Dividends may be paid in cash, in property, or in shares of the Corporation’s capital stock, unless otherwise provided by applicable law or the Certificate of Incorporation.

 

ARTICLE VIII

 

Indemnification

 

SECTION 1. Third Party Proceedings. Subject to the other provisions of this Article VIII, the corporation shall indemnify, to the fullest extent permitted by the DGCL, as now or hereinafter in effect, any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a “Proceeding”) (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director or officer of the corporation, or is or was a director or officer of the corporation serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such Proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person’s conduct was unlawful. The termination of any Proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had reasonable cause to believe that such person’s conduct was unlawful.

 

10
 

 

SECTION 2: Actions By or In the Right of the Corporation. Subject to the other provisions of this Article VIII, the corporation shall indemnify, to the fullest extent permitted by the DGCL, as now or hereinafter in effect, any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that such person is or was a director or officer of the corporation, or is or was a director or officer of the corporation serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation; except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

 

SECTION 3: Successful Defense. To the extent that a present or former director or officer of the corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding described in Section 1 or Section 2 of this Article VIII, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection therewith.

 

SECTION 4: Indemnification of Others. Subject to the other provisions of this Article VIII, the corporation shall have the power to indemnify its employees and agents to the extent not prohibited by the DGCL or other applicable law. The Board of Directors shall have the power to delegate to such person or persons as the board shall in its discretion determine the determination of whether employees or agents shall be indemnified.

 

SECTION 5: Advance Payment of Expenses. Expenses (including attorneys’ fees) actually and reasonably incurred by an officer or director of the corporation in defending any Proceeding shall be paid by the corporation in advance of the final disposition of such Proceeding upon receipt of a written request therefor (together with documentation reasonably evidencing such expenses) and an undertaking by or on behalf of the person to repay such amounts if it shall ultimately be determined that the person is not entitled to be indemnified under this Article VIII or the DGCL. Such expenses (including attorneys’ fees) incurred by former directors and officers or other employees and agents of the corporation or by persons serving at the request of the corporation as directors, officers, employees or agents of another corporation, partnership, joint venture, trust or other enterprise may be so paid upon such terms and conditions, if any, as the corporation deems appropriate. The right to advancement of expenses shall not apply to any claim for which indemnity is excluded pursuant to these bylaws, but shall apply to any Proceeding referenced in Section 6(b) or 6(c) of this Article VIII prior to a determination that the person is not entitled to be indemnified by the corporation.

 

11
 

 

SECTION 6: Limitation on Indemnification. Subject to the requirements in Section 3 of this Article VIII and the DGCL, the corporation shall not be obligated to indemnify any person pursuant to this Article VIII in connection with any Proceeding (or any part of any Proceeding):

 

(a) for which payment has actually been made to or on behalf of such person under any statute, insurance policy, indemnity provision, vote or otherwise, except with respect to any excess beyond the amount paid;

 

(b) for an accounting or disgorgement of profits pursuant to Section 16(b) of the Exchange Act, or similar provisions of federal, state or local statutory law or common law, if such person is held liable therefor (including pursuant to any settlement arrangements);

 

(c) for any reimbursement of the corporation by such person of any bonus or other incentive-based or equity-based compensation or of any profits realized by such person from the sale of securities of the corporation, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the corporation pursuant to Section 304 of the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”), or the payment to the corporation of profits arising from the purchase and sale by such person of securities in violation of Section 306 of the Sarbanes-Oxley Act), if such person is held liable therefor (including pursuant to any settlement arrangements);

 

(d) initiated by such person, including any Proceeding (or any part of any Proceeding) initiated by such person against the corporation or its directors, officers, employees, agents or other indemnitees, unless (i) the board of directors authorized the Proceeding (or the relevant part of the Proceeding) prior to its initiation, (ii) the corporation provides the indemnification, in its sole discretion, pursuant to the powers vested in the corporation under applicable law, (iii) otherwise required to be made under Section 7 of this Article VIII or (d) otherwise required by applicable law; or

 

(e) if prohibited by applicable law; provided, however, that if any provision or provisions of this Article VIII shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (1) the validity, legality and enforceability of the remaining provisions of this Article VIII (including, without limitation, each portion of any paragraph or clause containing any such provision held to be invalid, illegal or unenforceable, that is not itself held to be invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby; and (2) to the fullest extent possible, the provisions of this Article VIII (including, without limitation, each such portion of any paragraph or clause containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.

 

SECTION 7: Determination. If a claim for indemnification or advancement of expenses under this Article VIII is not paid in full within 90 days after receipt by the corporation of the written request therefor, the claimant shall be entitled to an adjudication by a court of competent jurisdiction of his or her entitlement to such indemnification or advancement of expenses. The corporation shall indemnify such person against any and all expenses that are actually and reasonably incurred by such person in connection with any action for indemnification or advancement of expenses from the corporation under this Article VIII, to the extent such person is successful in such action, and to the extent not prohibited by law. In any such suit, the corporation shall, to the fullest extent not prohibited by law, have the burden of proving that the claimant is not entitled to the requested indemnification or advancement of expenses.

 

12
 

 

SECTION 8: Non-Exclusivity of Rights: The indemnification and advancement of expenses provided by, or granted pursuant to, this Article VIII shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under the certificate of incorporation or any statute, bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person’s official capacity and as to action in another capacity while holding such office. The corporation is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents respecting indemnification and advancement of expenses, to the fullest extent not prohibited by the DGCL or other applicable law.

 

SECTION 9: Insurance. The corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the corporation would have the power to indemnify such person against such liability under the provisions of the DGCL.

 

SECTION 10: Survival. The rights to indemnification and advancement of expenses conferred by this Article VIII shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person.

 

SECTION 11: Effect of Repeal or Modification. A right to indemnification or to advancement of expenses arising under a provision of the certificate of incorporation or a bylaw shall not be eliminated or impaired by an amendment to the certificate of incorporation or these bylaws after the occurrence of the act or omission that is the subject of the civil, criminal, administrative or investigative action, suit or proceeding for which indemnification or advancement of expenses is sought, unless the provision in effect at the time of such act or omission explicitly authorizes such elimination or impairment after such action or omission has occurred.

 

SECTION 12: Certain Definitions. For purposes of this Article VIII, references to the “corporation” shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this Article VIII with respect to the resulting or surviving corporation as such person would have with respect to such constituent corporation if its separate existence had continued. For purposes of this Article VIII, references to “other enterprises” shall include employee benefit plans; references to “fines” shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to “serving at the request of the corporation” shall include any service as a director, officer, employee or agent of the corporation which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the corporation” as referred to in this Article VIII.

 

13
 

 

Article IX

 

Ratification

 

Any transaction, questioned in any lawsuit on the ground of lack of authority, defective or irregular execution, adverse interest of director, officer or stockholder, non-disclosure, miscomputation, or the application of improper principles or practices of accounting, may be ratified before or after judgment, by the Board of Directors or by the stockholders, and if so ratified shall have the same force and effect as if the questioned transaction had been originally duly authorized. Such ratification shall be binding upon the Corporation and its stockholders and shall constitute a bar to any claim or execution of any judgment in respect of such questioned transaction.

 

Article X

 

Corporate Seal

 

The Corporation may have a corporate seal. The corporate seal shall have inscribed thereon the name of the Corporation and the year of its incorporation, and shall be in such form and contain such other words and/or figures as the Board of Directors shall determine. The corporate seal may be used by printing, engraving, lithographing, stamping or otherwise making, placing or affixing, or causing to be printed, engraved, lithographed, stamped or otherwise made, placed or affixed, upon any paper or document, by any process whatsoever, an impression, facsimile or other reproduction of said corporate seal.

 

Article XI

 

Fiscal Year

 

The fiscal year of the Corporation shall be fixed, and shall be subject to change, by the Board of Directors. Unless otherwise fixed by the Board of Directors, the fiscal year of the Corporation shall be the calendar year.

 

Article XII

 

Waiver of Notice

 

Whenever notice is required to be given by these Bylaws or by the Certificate of Incorporation or by law, a written waiver thereof, signed by the person or persons entitled to such notice, whether before or after the time stated therein, shall be deemed equivalent to notice.

 

14
 

 

Article XIII

 

Bank Accounts, Drafts, Contracts, Etc.

 

Section 1. Bank Accounts and Drafts. In addition to such bank accounts as may be authorized by the Board of Directors, the primary financial officer or any person designated by said primary financial officer or otherwise authorized by the Board of Directors, whether or not an employee of the Corporation, may authorize such bank accounts to be opened or maintained in the name and on behalf of the Corporation as he may deem necessary or appropriate, payments from such bank accounts to be made upon and according to the check of the Corporation in accordance with the written instructions of said primary financial officer, or other person so authorized.

 

Section 2. Contracts. The Board of Directors may authorize any person or persons, in the name and on behalf of the Corporation, to enter into or execute and deliver any and all deeds, bonds, mortgages, contracts and other obligations or instruments (including powers of attorney), and such authority may be general or confined to specific instances.

 

Section 3. Proxies; Powers of Attorney; Other Instruments. The Chairman, the President or any other person designated by either of them shall have the power and authority to execute and deliver proxies, powers of attorney and other instruments on behalf of the Corporation in connection with the rights and powers incident to the ownership of stock by the Corporation. The Chairman, the President or any other person authorized by proxy or power of attorney executed and delivered by either of them on behalf of the Corporation may attend and vote at any meeting of stockholders of any company in which the Corporation may hold stock, and may exercise on behalf of the Corporation any and all of the rights and powers incident to the ownership of such stock at any such meeting, or otherwise as specified in the proxy or power of attorney so authorizing any such person. The Board of Directors, from time to time, may confer like powers upon any other person.

 

Section 4. Financial Reports. The Board of Directors may appoint the primary financial officer or other fiscal officer or any other officer to cause to be prepared and furnished to stockholders entitled thereto any special financial notice and/or financial statement, as the case may be, which may be required by any provision of law.

 

Article XIV

 

Amendments

 

The Board of Directors shall have the power to adopt, amend or repeal these Bylaws. Bylaws adopted by the Board of Directors may be repealed or changed, and new Bylaws made, by the stockholders, and the stockholders may prescribe that any Bylaw made by them shall not be altered, amended or repealed by the Board of Directors.

 

[Remainder of the Page Intentionally Left Blank]

 

15

 

EX-101.SCH 4 prvb-20230427.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 prvb-20230427_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 6 prvb-20230427_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Apr. 27, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 27, 2023
Current Fiscal Year End Date --12-31
Entity File Number 001-38552
Entity Registrant Name Provention Bio, Inc.
Entity Central Index Key 0001695357
Entity Tax Identification Number 81-5245912
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 55 Broad Street
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town Red Bank
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07701
City Area Code (908)
Local Phone Number 336-0360
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.0001 par value per share
Trading Symbol PRVB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Information, Former Legal or Registered Name Not Applicable
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001695357 2023-04-27 2023-04-27 iso4217:USD shares iso4217:USD shares 0001695357 false --12-31 8-K 2023-04-27 Provention Bio, Inc. DE 001-38552 81-5245912 55 Broad Street 2nd Floor Red Bank NJ 07701 (908) 336-0360 Not Applicable false false false false Common stock, $0.0001 par value per share PRVB NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://proventionbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex3-1.htm ex3-2.htm prvb-20230427.xsd prvb-20230427_lab.xml prvb-20230427_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 25 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "prvb-20230427_lab.xml" ] }, "presentationLink": { "local": [ "prvb-20230427_pre.xml" ] }, "schema": { "local": [ "prvb-20230427.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 60, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 0, "nsprefix": "PRVB", "nsuri": "http://proventionbio.com/20230427", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-04-27to2023-04-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://proventionbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-04-27to2023-04-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-013783-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-013783-xbrl.zip M4$L#!!0 ( "E*FU;OXG^X10H #,W ) 97@S+3$N:'1M[5MM;]LX M$OYNP/^!&]P5+>"\]65W+_8&<&RG-9#:@>WV;G&X#[1$VVPD44M2=KR_?F>& ME"P[2KIWE[LT:1;HVI9$SCPS5%H?)A\O3NNUUH=>NPN?#/]K3?J3B]YI MZ]!]PMU#?[MU-NS^RL:37R]ZO^S-5&)/V/%1:ME$QL*P@5BQD8IYTG 7&FPL MM)SMP4 8>OGOCFNRF.NY3$[849-9<6WW>23G\#,0B15Z[_1%,C5ILW5X>=\+ M:#E?V+W3UMEI[WHAI]*R-P?'K<.ST__!6O>MS+Y5*2WB?TZ5M2J^==G6^7 P M*:^U/^.QC-8G7UN-GC7R=^&$(VM-/O1'W7JM_;$WZ/:ZK#WHLE%O/&E/>EUG M/5SL'HSXD#KF?GHBZG1ZHTG_O-\!']5KPW/6'W2&H\OAJ#WI#P=L>/Z0BCZ% M+7$Y&G[N#="8]=I9?]A Q_<:=2;(KF9[T7CQ[<9*!;_">]]R8R5L[6_*)-0 MX+I'!^]D+Q^=\PNI+618.<\B@SK:KD4C7Q01]HUCOF[C&*9 MS*U*&O5:1V6)NXQ:=+B!T0UV_+>?CWX^8&4\2FO*(O(Y6 @4U,P(O?32IEH% MJ-&M4G++3!8L"M6E*6M7KXW]7!T5ISQ9/X/[,8&;B)K'=IJ!5TTUA VSBHED M#A!"I("?X1\@*HH8P&2618P' #: %GS*I;02Q$"DK182L%,*B@847[,I+*/G M/ %10I:!=AK7K->Z[SL7SPAZ3 @Z'WX:33YX"%EE><22+)Z"0P%'9@$1A*)E MP%.)]XQ5P95'Q2[*X&G TX(O(>AD=J$T!C_ G30FPV@)*[YI'!T=T3_"'DSL MIO(+T0SUVA33>,]IHTW[O\C MWWBS3(,K-4^ !**7$V61(T0RAHA/.]([V^-WL[L C "&+0 BL]B,I(W-W#T M:69)%[^>GS7??C>'%,M7KXJ#*)FT3IQ(AG&NF% 16H($5$ DAC,#%+(F0V]]M(:-<; B?D^2WH,2XAPVEG'K= M)%+>5PQC0)RX;8%W.3)S\/K*G#QR"WS3(??-VX-WU!V[-W6/#\#5+D?'_%K& M60P)WF)-#^PUQOU):&E>A8:3!8,%G%DAO*>;,M(J9!1F( M"< GS% P'1SI>ARZ7JL*#H0Y'V! 'J,2N(#!G$\CD7.+\@B8$!L46V$-2T;@ M[<)RO68ACZ'>=!>GFD@\QK29#+- T@,91&%0H=%5%/F,"\U "LD+5 --25L+O5*CF&I)^,O+IH$0+"VL92CRN MN[+U<*5M*^,NF1;IG)>(\D.]1A(Y=7 (5.$0Q.W7,0%QW%OB@ V474F[@ 2: MA%XYM+>8*_AUB_\+@5"$LG?SE5W@<>DR32,(//@0I!7V4KXB=U)JS%U*8_-U M7FB#M+ALP>(2^1N>C]2:1ZXV)&=\!54-6#9?UWXQ]NC[^Z6V9;S-T"W DWIF5& +AR\+,]9K%JB7R;&+6WA375=I!6O*)3&G M-9,Q^ I+WP+.4Y&(F20%7FX6R;<&.!3MF[B#42_NEOV+SF7 72LIWP5,)=$: M\"8D;2Z:%$$8(V*2@NZX.6&OMH')!8 :G^4:](Q=>(+FC4GZ%_5*,?8_+%) M=/"?P78IR$3VKQ;%X;_8C;09@<]F@7#;8#9#G]VB"9G/N]6I !'98BA609!I M3?O.FSW@F;.BLS\R9><;ZMH*VK$\"'3F8A1461HLX>*577#;8,A#9_2K2I&5 MRJ+0S4#5, Z'J)]JB4.4KR]S-S4*'^D=+VQ9KN21A^")#Y.;OS,JLJOH#_O[ M[%R**#QAEY"SFS#PMTQ 10@#V/Z^?Z&DU>U_SI??T>/'U#;95&F(3L6ULX@' M5^P898><% M&I E_]:$W1W:!6IS]-XF'3Q M-9H1_@\U@$^P1859,"E>[;O^U E+R99E2/SHQ'N*5BAAZ!!!Y'#SE'?1]QTT MOBMEGZZBKS=5Z5T5R'8AT*@Z8BQJ,BII;FM? .%X24W]<(DM1^*/6!:*ZU0D M1N!)Y:LR62X(* W"(_#*YI:;$S@7E8^>$-.QYX9.$R]W6ID;$UCEB<]-F5_! MPUIE\P4[P^9:J<,.%=9<"U+".,;I*)<74V]+TW"M/CQ8*Q?-2/Q"Y'UXS&_0 MWMMU:%X/$S<7UT'I!88;O:%=P^9CMYU9U"QOWQ5% !W=LG:9UY<)8ZS"+1]N M%9HWSAPJ:/.FP0 "@MHB@I4]070N__T"=U(]"6#I$V]UCOCV_ 'I" M^U12IP&_J!R3>R*>[_K>U_MOJG$Z0V6L1<4K,V)R\X)GOK?M4 M]5<#6[V8_;))ZL[DH_#._O^]J_-@ M*#_$/WIS?P6'?RSW!U!+ P04 " I2IM6'A4"GA0_ CRP$ "0 &5X M,RTR+FAT;>U]ZV_;5K;O=P'Z'WAZ<0L;8-(D?4R;Y 1PXG3&0)KD)&[G#B[N MARURRV)#D1H^['C^^KM>^T52LIS*M>SR8' :2^+F?JWW6K_U_!^GO[QY,9T\ M_\?KHV/X;X3_]_STY/3-ZQ?/O^'_PK??R-?/7[X[_E?T\?1?;U[_]U?SLFB> M1H\?K9KH-%OJ.GJK+Z(/Y5(5,7\01Q]UE:#R[ S^3'31Z.JK%\]_?O?VU!_ZP5PML_SRZ57CTF_K[#^: MU_#5BZ^+6;UZ]OP;'! 6__Y&IEUE9XMFE[-^_O+%Z\^+;)8UT\FW#Y\\_^;E MBQM>PAW=^=U/^^/K5^_>'D\G1[^\?GO\^C@Z>GL.?6].[G.S?E]Q_>_?;Z[>G)N[?1RY-W<73R]M7#.[>(K4A@KV9\H*:38YVK M"U7I*"FK55FI)BN+P[NTB#]GV^6SK$@UCO[RFAP5 M1:ORZ!>MFZPXHYOR,#I=Z$CQ%TO^(BKG4;, XJZ]:X4?OJ_*<]@4F&+T,BM! M(!;)P^@ ?AI]G:?_;LMG\(Y7CF'C^%]7],4AS*?"02.=\R)QO#2KX(\2!E=% M:G]!>Z/,CV 6;;*(2OBFBF9MG16ZAM_7<(J7T:HJ8?/R2Q 32QW-- RA:0RS MDGJA\AR^B!8:!+-6,-*E5E6DFHB&356CZ>4-;%X<763-(H.W5O2OLFUHL(\- M_&HZ@0D;L13C!/"K6:FJ-%P*;U[D[4-WBUZ:AX[-0\%.\9Q3#72VA-5>I7+L M^XW_2Q'NDYLAW(\KG60]RC6?RF6GJ^>3['0R3%)\]:]-2S 6CJ>*2Z'&50M7 MO-;XA?R31P)R2^ *ZS2:P4\KF H1#X[5O_KX-/PL8#7X7WQC4YYI>A.0:ZY5 MW40*7O![667-)0Z"=(*C L54>I#RD%LU.).FC,Y+I&+5^(N*B?A#+G%]WA!U M68/L0HT'-,]X(YB-X6X\G$[^N="%/M=\.HYW\$3F*LMQPO/L,S^URE4" Z]G M;+*H59452;:"*Z$_ZZ1MLG.C'QE+Y:Q'5_Y]F;XRMNRDAJTDW$&QL=9'-D%X>QHR4@G,H\;FF0 M_X -P&\JO01"12ZT;(LLH;L*H_-0,5#2='*QR( J I:!8P,'^WP9F4^$!E.M METS_,R007<,A1D#'L,Q#O(AQ'?)^+V*";J4$#)ZFIBF;"99\ #*_@:%1U6IX8D"LH< MMXUFJ*R6(T7^QX=E5B)OM=YY=#=WMG% M?NR>Y$JA50Q7@9='.P OM1-!*6"ON<(WS^%<"QBV@;-<+<#*P977&="SJCH4 M$.E_M]EJB;?7'X9W!F?-%[KV9D'[5/C;-ITD<(8+U(#IIM -%AE(@L8]"[0! MSX8G!S,&CMBTC:&DI'=_@'>(=,QA&98? #\J- EZFO!T8O83)W"1U=J0PAG< M=1#;\SEROG,-YP;''/*9WE'4X<.=!X+M"5BH\&)1\A;&D<[8DF']"O6I>2-Z M@+FO:/+,8//@CEPHI'U\IUFU-QCL/3#IM,.W].=$KY#SZ*++I.6!VAECG_$< M:T=WP!IFO^/6TS1$K9AID(Z%,PP]QET.J9>X>DMH,YVHMM9=XB4VHR[F+3(S MT1:)>1:PA3I]&!V%6PA[4M)N"(_R=)J>2C0KVX)4+M:)R@2.R!=;=AH%$0[L M %![0XHP2)FTM=2.)Z7AH86"X33L)QWPJ#C]L668]_W7@P?1SQFP[Z?1>W6F MG\&@_VZ1I\"[HPOS-_R#ADO M*?-VW,?'=#3A)/T+T!;=OS;[(1S*)S 6P^6< F:>N5(#D#US$]T]60 M%X$E"XC*%8:D4%M:JD]HZ1NWQ&/1BD6JHV5_Z7M30P4&5;_E*M<-6P7A-(S6 MTO5<1#W'106[?,8:JLI7"S731&[L8S".C?+"J& J34G6HQ;4M1+@MV ^H)K; M+F?\=Y3DBG\MWI4*M("Z(4/$Z,1JJ8>& ]48-1*R>*Q0+E>L&K':@?:.\O4% M[_&8_5;XJ=%+X%S@$NB.O6&5*86JTK"==H$B?)/EP HT/]Q7_TDQ#/7_8 )E M198I:C.@G]C'8NN1X4EMG@3?46^[5%Z+N5J";8*SP /YA&J=C(LN*;9YZ04= MQ29M*W/J<.-S^;EH,[%<8-*8LX)T'_90#6FM66V,YE'M^;)E/-[M(DYM8,8P M+'MK\;S)U-7G6W[9:X,D7*SEF7_ZW=OQH?V%A/OW-R/<_Z*<)T7B7U45_9O> MM28>Z<5--EY9)LOI!'TFXOK#P;QH:H41[I1]07Y4 W^6U76++BG@U&7;U W\ M0TQ<+]"1J%76J%S(=4/T@UR#@TI$WR'J$248X0U9R)O\OL[+:3?.R8R8'T>W M R@^TXF^^N0,+]E\2);GI2!Q4VVM?5ID?ZN##69-1[:RIV:1E(0U7;$S)W/^ M)B\+ [T!B'S:PJ M/\$O9:_K=E:3Q=[0%-)*7:#VV=/G1L5A+Y:Q'?O^X6;8][OJ3!79?VQ:R$,; M<%K'-R5:0\1=GK/OF/C"0F45O=5$A(!R2 5G[[GHZ^9GENFK&?NK\ M;#?0=!+\N#L<$_M[GBCRNXV3LK_KS4KQG+R!K&6!(PC/0N/RK!3[P;)8U-S1 MHJ4)BEF1+,!L2P\8RV&:!:U/I1E67ZY0^6;C]W?#^\4&S M$&5#?="UJU8K6#Q)W>E$IF@FC4[WA"1+W9V3F?$=I]^_%!OZV\VPH=]*O G/ M,)'MS"\;17' MWB_7L#WF.:A#PV=943>@(@F7O*@RUJ)1$TJJ;.8E^OB3D@RGSL>6%:8MF.RJ M!26N@AW .'935H6^A+V%_0.F=C #[4Z43&!\-"^[#IP[A2\# M[=P-9I7\V-<^4:+1CN.[V'>(ZK ]WO[1K'<]=C<59E-L=$5$\KT7W!4[C%)4 MYMEG>,FJK>I6L52!'X.1\O(23)/:&D0FB;4.4S_% J% .SG8\-R\^##<@AD\ M7C:;O#:E3\Q< M>[N\:SE@876M5K&I>HH$3:.C25B*Q*WHG;B<$A 61J/%@AR]0%^^B"V"KD^> M1>]6=*N?XJM%%C^+?E-YBU__U6*R0V4/0832WTRSC<^BT\L5O/^H4K,L>1:] M!4;%6_VVQ U\$H0LS5/XS1COW>=X[SUB!;M3TF:HI('L$*EAA4])JL,2(/;]TI'+^A5O=Q-=ADL MLR);MDL3V(5G6<> 7S311=GF*7DP=0*/H-GN\7 M\SJ'/:HTCTK#HQ?:\S*8Q-O49=K*UE*.&_^S)L?$G%)A*2>/-%8.!A>-;-Z0 MFO<03;SEJG%Q6]X.6(Y;2V$/V:;_ M->A]":\V9QZ<:\I\-(^R/BMK';6;/3"?M_-._'@SWHD3#L9+/1A[V/H%,S$E M?*3GF*AJ,ZTM7R,6ZML=L76;B2^22(ZPE'1LJ-OX[=OUU7GKMA3R<3DX*M)TTIX[P^$AW MDNM@)X"R117N42JXH4@Y_ 1SH]F:YGF>JP1V^M(, KPH-]D29D3:D:5*M?#W MZ<29A.ZLNC[-LNHNV62L=G=&0E)@\:&Q;*?MU41(VA'JJ/@ .0%D(C7G.N'; M%QE56Z&=E[9-AK>1>1"WL2K/@!%W*#\"*(O:?\],XI-O# MKJ.%V'7=5%G2P/584F8YV[ID^U*N-==X28XQQTB].8("C;]G.G#G[);=*92, MO 0FE[9DO0J>0.5\&F>M1ZOR@A]"=T3LV[+V<3\XUXVB8R1V#+]I140W:M;F)"5A^$TS"H\! MMJK-&UY56EH%@G*L.=: Q8;X0JF_X&FXXN!*8A,97\2*(NY(H7D>9H9$[UCQ MU"[&?@5KX?-:P[%BN*S!]5H2;>#Q@Y[GB6L3Z+1;'MOM)N9$'@NW*\XSN)95 MXL40(E/321)Z;/!5Y RL/1G M79D\"20V);'PJ&LX1J'=2(E7'=MQ.OECQJ,MI )NP7:M$56CQ%78FUL:R MH1FMLS-9*,//B+ \0K%53H[@/6JEJ^RRAX;K2CTI2W*450$OO.(HW01OS'ZY MMZ."J>A:X_4/]ZOVJ%;! 'A5,MPR1W_F5!NF>%8LC(V/%.)(H'_'1\&Y%\O8 M$B7GT0U(S@]/Q4\N$?8XPZ.WTBU.'*M^?1@?98:^R M>-V8S]BR.U@6!O!\!L!H0:E"SQ JI$J%?(9XNH4[ZO+',MW MKUI@[!) B> /C@[7U-]D6#.S9/ZH8!7$$V'LND5##84A'NDE#X.&G$T2ZNP# MG9_OGQY(C;URWK@/JAOFIULA52S1PT8M+Z30>L[ M1_E[@VIZQV%-[_XYD0N+@E\,O.@C)=[E=8WHIC>&;OIW@9-ZC\$<+X3J_$L< M=> @#%A*IIYR,BG1V.0B,)NUU/.E M,V-S/D^7;V AV@P !#IJJT'@5;LF3GK/8")LBXO-FMEL.@0[E$ V:/%47""_ M&1@V"#?8[0(91QR4S.<<,Q(J"S92N^2*ZT^D5Q"[?FHQ9XX@:!X\8S!:*?#A M+/6!%;&["Z,7I@SPX72"!]#6UNN]6E28>2(@SVLW74">,;]!9QBXGAM7-089 M2DSR&SI5AW_H2RGRR5-L2HLK']Y)+NZBE+R53(_8"?NP"$J5/?;.DTLNS=VC MX.H "GL'-PB3*=:.(=Z]C)* EHP?C#D;YA[0XX6^R"^GDP3SB;0WVB);V6P@ M?)\)YG$-.276P.Y<,4-Z@WTB(V+'N*=)!+.KI=04DHM85T5ZE7L(F&J>Z8JX MX)D!":K(,W>N\O$V[\$B#A*XS;]R.9B?I,WI7I[71PV]JJ=4JT7SE& MD3R.GK/#&00&2\C$TZ0"ULF2TE&-2_0(E$JP5-Y$M&996 ,'-A()5C$@%(3+,BA"4UV*V7&%&83BQ:&3KJ M.1G2:B8D+6M=G1OUP)")VW\?F0!>Z#JWRIL.8,!T*+BWQW&L1L+TB"A5*(*M P& MP7)\T!<7ENUKN(0PS&1*?SL@.).'PDD6S/R&*C8MYF!OJNL2D/KS#8'',#=Q M+1.3U.6>.14F,]G"8(0N^@P#YI]"VH"O?$FKY& MH.V[,="VTT#;=V.@;0RTW3[EWP[_B-_DL1Y@WA(7[09RWV^ EED_FT@[NZP7C6F_;BHHU MF!U(QB;;AU09Z@,SD7N+.<](@'NQC%M% MR^H^9V!'AA&CJZSI?D7K4@H_C7 M>Q?9K;B"9;WG:+RR>[B,6X6'>+NN6:.Y>J9LS+1(LTX^Z1\:-#1U_0T'>NY) M)?P6T8D^^(D./'TPD^G$*YF\*)%", I2!2U3N.JKB]E*N?DJPP(YTR$OQC)H M:I$'_]0/^%N!EZ-J#Y7;*L61:O9B&;=:!FWM?;@@OY@RCU>N]>*IN5A2_MP+ M:_IA@^L'-9CHNN>&6DYN%T\D5=&][^JVE!S,&^I+ MN9.VE-$UNE)RJT;[9 C5"186RG8Q-7_"([U&Z\H[3F9_*6YQ([6?@T#UIXL. MZ'QC^CZ@-"+*N ;\//U$D&T,W!(^@/#OVV+;#R+2@SUTQ2L"F'AD$^ M%0+5FR912CC=AD[OYK5$<^$HV[P\]E'N0WS[U+W")C_@P-3!U'BFKK!*7=HB MI9IPMW9R01$X$/] @(\V>7=5'>)*#/B7K\;.-X#W743[[9=#[5]=%Q;$;\X$ M$O#:8/P4EG;8^Z:(> !R?V2A>[&,+5GH#=5A?'")>PBP3VE[S$J/_%0DO%6< MX\=D"M\1#1%XV478@'X C,1J!WZ>H =GQAA;/!JE+ZTL:ITAS< L3W8WK$F!YQ^Y3_YTKI&RI,^\W4 M!;!H7N_V8(F'"93&I^%*"J1-PY"N;[!C2,"9J(Z1F0@7J9H%_">K_^U7R,4F MSS]FA%8L5*@MIICK1C&=#)7)&$ .;CG20VRE(4"G!0NB,0";[//H2EJ8A,H* M:J7K5J1R%-EG"Q]BVP%]&H\^PMX,/!\+WJL:PLWKHZST]8%U_0KG6!,U"OG] M7L:6I'Y#Z=)'B8'OZV!".JV\@^!/7HUM(?S76*";\1_)PY'G'6W9H.*1HMZ4 MY.L+8.OPYUO"Q"^SHFU87>[#$(W5VEZ3$EE[9FJ"=@GKLRQI'I(\;0_HX+Q?>4LZFI=? MI-)RU1@\T>W+@;HN41=,*RN_V&TNP3V)K+-@3[:YIX'AN'ZC \H7OJ!H&O6$J(-8.SMW>8!J MVZS A]/)4%O$7NF?"72XA@U=VJ?\*]N5KV<@12G13<=_(G_9B&;=:^7O#IFQ'E._ MA7:LV%Q M-WK'UNTAM._,U'54?,=OWE^*@&ZH+(Z!QTY)>?227$Y8.03)$\3X#9A$0EY8 MIAWE0KC]Q(58,K8X0X ?KK-EFS>JT&5;GJAJ,RI?2I,.S ?=.B85^L MQWMK^F_IS?GMWBW\WIXHY\U)3=^(SWKW1<\->6U>FP 5:CB0_/&])]RK (6+2_4AD\3+]HD,:)/\F&)O)I9&RJ/G(HF#WI-A M#F,='1!ZDO>##M0@ET@@T%N:9C@\E2IX*&?S" [F$SX^;PN:P"%F/9Y6W!E" MP ])PA[5=4;M$^Q2N)]C^)U]LG;Y4IS4Z&IPUQ8(#JR-FH.\WP^F',\!HSO.X-*[E55S[:^"AF6#,GJ?I!+UO$R'=V_Q'E M++,J8(S]0?S7+=%<6?*:GMD&4%)F(#V(2:<@&Q]3PSII6C:="2;Z>45-$-$O M[#G],?"U7AE@$5YY"R6/@K?,H7*+ '_:-/$>KITS!2Q+#HEWL=[+C2I?IN:8FPE\]3$T"7)ASN76OLG SNAHO%YFXEQK.+IBKS3=8?F;BN PS27.:ET_L^X:_5DGK>!9"-Z# MA<1#BWY RLLR2X+W+JM"7\9\;BII,.>Z+%)_ N4,2(3]4SR+K*B;JL7='QG+ M?BSC5L'U0O>?2/)N>;1W5=E[M^5=M?=R_86,O/N(#JQ&2@Y$*S"(7$G95@Z' MC^F;<>T0HIX);Q-S<(#[P!3Z_&!K-]U(,GNQC%N%O;/^:">+[4?1 8,>'%KG M_70BTI#O)'XHXBDK$B8ON>NKLLZ,K><&[+B\>S[H\<[>D67<+E*:J.KW-7E7';7O751PB<-/<2.-E_4M=UAO"B'M'E\&)?ANH84 M*18/%PCO6]IU#>T(:OCP$QN8%*\G_+G"0SO7_MIYQ2/%[VD*+Q4<::H Z'<4D=;/&#G)P39@AV0'W\QDZ1$H MK"F)2:E/-L$;PI^7WO*P8;1.E!3_EA>%./METF:A-A1)VR]FB+7#IQ-5^\F) M!OW&3TXTQ8G6ZI!@1:="UX#X;F^QWSWR^TMQD1M*U#GRR>6C1RK,5MY2K)_# M?Y(]RI$$2FIAC"5A+J8;E'4:2; !DV@$&SV_C#ESIRH1PADCB(3%F FF$-&: M1Z^VX8W[R$.P-"7W"M#%=$/C^"S MRF'1P:%T&VI,)ZEHBP',?72"B.+=Z?FYCX-)+]TE(=6:L\7#67>RT\G:HUU[ ML%:+DCN5Y-)*SN;5B)#!EB$%W'$Y(Z.+4B<1JJGX"XX&(,^,$*\,>ATTURYR\&((VS'E;,>QUPHY+2Z^,-\%:#!S+.J;GCB=G=5)+$\DXYL)EKKACO6EY4@4\BK M&2@#G1M5B=A7(0X''(,U5"@&U[V:LTO;T@D?1)B92I]E=4.FC433R5*'H5RHWWA7'T:7M3M^&+Z7CF__^A3JG+C5 J65JLX[1"T+G0)O2 =[P M"_W"!J*5N0Y8+7%LEK54Z5 ^M[.U^@NVYP3;LZ L,8))2K@_D::_O:>X4U:E M&^#.-O4;3YT22(>T@MX=9[UF#8UL?=K7TS&FDUW0RO54C8#! M#'6.)G92=_D/7'-Z%?GYO&T:1>,>+.(@V:5H),)"S#YU:10N15TO4,MB&I4$ M'Z#+*INUIFT8W,*R81-&GB%X!^O&7?M&_1EL=JS&\)[)"N,7M7@JP"'.-.4[ M [^IY:7Z,W]NN12Q15'E0#ET/9Q=K@7#%,H-_I/,+&-072'1?3-K6&P;0^>: MYHS .(*L)A*6;?F#K"/:@G-4.E>-K!11HD:.L0>+N$:VR8]CMLE.LTU^'+-- M[F2VR7ZSD?W.-3G9WV23:V[_M4!)8'2 Q!JV:6/N R(K@_"]FKDU B)[R9N1#(MVL+_) X@E=N"[1OM M8ISA14? M__W5&US=UQ5]VFIJDQWA'OS+T\(Y=GGC M#1 $84FNJ"V%1B4CF7#C;.\A QQB6M+7"*4ZG1!VMX,^P: *<1QMO8S&-5>I MBEKHHJ]-CJZD3VIO5#<3YY,CCZ; *>&6<,!&$6#7>5C]I:?.,)(;86VY6 M"[W%CC_()_8R>??+ !2#W8PW4+ GD+G,(_CIA:ZN,RFQLDU,DU[+;-._WXZ2 MQ+HW2&MT_MX5T9(2-KN,'9*R=U]:AA&LA&A[KX[[?*SPDLEQ/17+^\M(7G7&,_ M#YJ!6!L(ADJ3YD*YHK@W>>YBZ(%L)2]=E&>?^GP_CABQ$MX%HX$ (^U(R-KW MU1).SF<8+&VU3'NDV_U8QNWFJU7L\ 8R^4@WRBGMG4A!',W:QF"I2=J.C7@U M9 =P!3K%8(Z%?L* MS^Q'E&>XIBN=9B@9DQ*M4EOJ(?JO4]9Y'*N#]$7S&F-\5)#W<1FWBJKTIJR; MCG#.&CE'O+2^!(_ON,TL-8:*.$RZ JJ<,=% MO^L<[L@X]F09UPB-_S2&QG<:&O]I#(W?R=#XOK.2/0^.WY_H^'@#!M3!8TF< MW \8AC&NOO:L/C*$,FI\%UB&ABZ0U2H'MHT>EEQ=6'WX5:B4GQ0!2O$:C=DS M<,DK8R&]7%[NQ4)3@BIZMZE"VOFZ+U!I7:G*I,/&V& I%>49_<_G*LMIHJ:, MR?,)F]S=H+@?E&&)1+NO*0L>055A6G[ZZ#-.7\4?UEXC@POX6IL:1C,Y=J+1 MY ;\6#P!# 70TS!S@8G 'TIB;IK5&",=:)/L]=227L---.RF]*#78ZO@,_Z; M'9W:E_/BJ;(#(9Z'%Z*6)?BX#2(ZS (-+IO-572[P#G["V:9M0E8G%[)D%!>M MF\'7;3:/IY-EF:)%BO0Q ]6^7CCK3_;)I#0F_'V88<%9?N&V3;"0Y#K M5E3:'FO(B\3E3]?2'']L&IFL<\39;*-@<7'$'2!@%H9&@\[JGSO: M[;>OF( V_>'TY-6;UZ1-G]S&4G:5%WHKNW#8H/[B.M&+&, 424JX+$IBF1P/5/.&)1I'>V.O)S>EBZ%\ M0QZ.&L2*UL5_-0L2>H7-^6(7K?P&P1A(K[._BF'0(A5M@=)/-!5/)::9=]9( MV:YL6FS5;!#T6%":5!FB&L"_5(JE4QP#.M M,H*>+;)5'/U.S5:PGWM;4:RNK1M7?4BL9%5EM:??8[BO0!BJ VZ%R_/F;)Q: M-(+I9*YU?0C#M^D9=9X 4PIKW3C@N$3??VT5#ZP'YV1A/$CN5\.Q0CPD4!2H MZRYF^#A0-7-&5%5>2(<=RH:BK]V]F4ZR>?"(2J01SEE9IIC>T"RD30:6^[*. MZ/_>F\5,YYD^MT3#N'MH%)4K6ZY.F7UX>$:K=7G:29BK+/F$I@)3D@$,H9@[ MW2&KA4JY6%$FI:4]'LV(9N=/WBEHI'.3PDL-NL@&Y#AQ!U )Y^!V#_?;G&', MM:^Q=UY<*)K9F4J:*; 'A6,]/WE1E#E573>4G:6CY]^&NG8:['C\:XUUCO.L>,1-K MLSQYBC;+D:11OB35]X15WP^^ZNOY:W9NR6"SNS6F3/1G6S*4S-(W9:)K6#+L MR,V:[0R)B-J E FFEBJK)>&6D&-WKLXY>7TWMD;W[=N8&M8/N%-;(_HR4V,Z MV=;6N):I$9&EL;7A,)VLMQPH^J+G^$JZ"//WWWS.0.TT4K7.J6>)]C MA#>5(CW8Y>09Z;.R!O^.2;-@*MVDVA#YC7 /#V>GY8#1JP5F>7'-'P^&7UBG M_M Q(7W,JK)%,N:)NF@@6RSLD>9H#[X2(S#U*FLX,8X68W8.IH"KR7),F,5D M;WCU>0;LVY2%X)RR*FF76(J8.+\YIB3$7:+'[/K^I0VJ-^7HX&WS4NZ/I0L' M%3.X/UZ(AK?)K%XOQ9"BX8)FO"2"M>=4DD(A)=V<=M->,"M MVBB3MDPE)-^1A/9D&9:$OF<#-#VGM/OW+O/FM3!8)J+7NU7B0S!6(^@&+1TC M1%*3U^+YM>T5HR"$4%+G825+,Y8;>6[ABOMMA'O1!D'M8-Q4*NDS\+?&TB*I M@+K<05.>,160^9&"*;GDVHPP[* I82.QV*!&@!TRIR@8LT700\ET15T:%@=K MG)O9"QE3(28F8;&B+)&8;.Z2O-J\R4"V:71WY%S2>/0:0MF_#1U]1]J@F_Y%ABFZZ%C 7 >N#%OLAM%=RU1./= 3 MF4 +T8';4W W-ES<7P6GG1&D M#8R-!3/CY&7W49>'H^1ES'R"]!IZK;E5"Y3#X&>/FM=DPK<[;N/X+"X)4SA@C.FFQV8P>[PIRZ+?5/WI;4$BTBGP%-)R1BC"<#::W;O2%"_O;1=^:G'U4U4X6N'[S[ MG.M+G!)YY)X\>O2$%F.P@3O O_W'0AC@3I7E0/S8XS6X-&HK9?8:Y@Q;A"$D M@A/&G>]? N\@*));YG9@M\X?UJ_S<%LV,YU\ 9\99=^^+.(@/<0\";@IIEFW M=^:H!5FOY95ZL_C.'A[3ARKZ+DN-%F_V-L75R.M;&>AI]*6D7!]FA%\JA M(F;K2/6 ^$7G151B+C2N3Y7A2N9#G]XZ+QL&1D\M%!B;P>9O#A@,5PC6$M- M:&!/V7+9&HNAO5+9GON00UEU=$[]RDP.5YARDO;B9#0EF).+=7M8C#:KC)\T M;.%O7;.-*^-PQ^&R# W5*WZ49)VRNN/$<3\H7!]2L4@881T\L'7M4!E(P.FN MDA*Q*5[L(E$D-.BV(:,YAZ4C-$'.R%U87%'H N1(HFTI.NL]BG,D55.7.)6G MT<%C)BX:(L,Z7AH#3304A'84SF$2NJWT4BK ?3CAP1D[.1;;3GFY]8;$K*T MN?DE)< BU%FE5@O2T7,J;,"R$*_J7/K>F:V[UG:8_6=G/9>/>"-$5PYPZ 4Q M,D9QO^# BJ*$5 Q48%[*$LOF'2:XW ?%5]^&*W9U. M:'MYLW:WQ]OOT(P&15PVW).ZE)Q @I$3T%FOKK] %#C@X\R-)532F<"5KQ[; MF>V%@\PZ0/]&#M!C/W#&#L\3C'>[L%\WZQ19UIH0XKI(L5"T*14D4!<&,YE. M?I)6YIP[;F+N [%\@Z2R)A OSE6<-NH1O28:K*2':: $2DY)E8QBBG8AW?;? MP9JHT\QB%BXX1UN"MIG1\DUVS?9;Q+'8#<7$INU@J#XJKU.%W6TQ!?4NZBU= M&N#0F1/77'?HUE+KJV=#>55!+E3'XO(R&$VO%I.;2+E[5R524:[4B=>^ S,: MU^1RK2MU&!PU=DE68(NGFE%OB0,23*YM"BFW;R#>[.4>D$:[]8VY\QSGGC#. MZX2AGXQAZ-V&H9^,8>@Q#'V/F(G5PGXD+>QM63QXC;E4=78NYAR5_U'VY5/2 M&;H2@]2!-2+9 VHB]RO8$]0#R?.RQ$-.CR :C7ED\(R6:74Z0TN[ UM'Q*TB M:JTI?_$:.J-DOKEJ&><<[R!Z9T4GR2^(:5*Z&3K,*BVH!AB^M$C@!H&.PURF M]@K6YYQE0: 3N]^@7L3@AK:W_%#9/CGN$+@K42N5& .]^Z1-%C0_@GW+N8F$ MS0EE%V!/1P33N69T,-R,/.RA@UU""BZ[Y*P!1 ;#_AEH-&*#CMII>"6U'A=L MAJMS'8WW4>*\C,.Q_37<7L.Z,@'^SM/[?6-;/TGEA>01N(85/HE2)QH)W]!% M,1"%7@)"D+;0*1<>*HP=J&!EZ\24L&ZNL+W9NMD '>9+4X%]F\\5*:H:IMYX M!5"!F4CUJ=;8"VW(S&]G*,R'=L6$V@0^E6A'\UN%!25EK=\\NRC9/ MK:DTG?2K9 :#(_296ZH3 %TOFR2;WWDRNF_,&3DNXCOH" MDFNN*PN?.>QK9[C45AM!:VO"38?-H!WFEJ3L.M;"T)6M=9[I0L\SRR86.B-1 M^5DGK:U7\!#1J$N/K3:7VS[>VCU9AKNUC^G6OF9W-ZK<>J79 M014;H/)2R8:X8JE8,B&AXM5/(? %2JUE5M<6QROC<&\MF;)&FEX7-%!\?2B^ M>H7(O0*4;6P+5)L),<#&RL/ A44J,?I DW%S60:9Z*X5Q@6E%,P43P$7 &ES M'#(A/@_.!*'-[" :V"&14 MUK2:6KDY*C\(DUO\GU&!H_?!(>&95U+USU^A ]+% I:Z.C-0?#$7'J)NC;'+ M!OWSV.(1F08"'1I!C6AZ3C_$;]9TKW/*XM56JM/]X=.ZE)C(%YD1@4+/VO+P M5@Z;%, N>C;%IE%V#,S3L2^FDPT@H'S!$-G$IM90SVY;$KM> ^_J8MT\\/!R M,L(\*H6=JVHL"GM,[F)T1]RXAUO>O(?3R;5)U9%I=P/KM<3JSLYHC*M<%;7D M%[CQ*9+E7D"@JNL'E=QZM VY73':@G7-/1O[P;%RR ^9^#:]X:RMY M\Z1IF$1?>=,W&O!&ZB_YZ-*6TVV%"HOS,LTKQB"\KR-XT.9=VN MQ73/D.! 5@IR]U%[^3_C$WT;II9WV83O0^J"5Q7=[E'R7WOHW>$ M56=$KR;-C11M^)>8W@5EG[$[C'6_LZIL"1TG(LF+NIVQG6,"2DJL;ZTRO:78 M4@A0X>1VJD%931J>U!67RHN8Q[OH#K-?(RYJB5TOX=[E;3K5>Y8QN)7M-Q;VK:/>?768Q>#B%,8RI@8+,U6%L#VE M=_@FP&HV,0KQ8LD$&5[A[I3QD<'_"1)^%/#W]?Q)P!ON "?]47.P=93Q^ROC M3S'$UVT1R3X6ZQ_!Q#F5APDT_)DOH[+"8/%2S8,(BT(M;7#.?XT!GKG4JI*, M+_3G=.(%J8^R*WU<@;$8P#D*>W@ U!=@2I+T^09ABK.SMM*;&J9V<+H["YQ. M:(62 -C6'+Y$78'5 5V<5>J<_IEC"1551=&?=:.6*P&MB?P3Q2^73R+^"]HWR^ _)Y3@=F9657 MEEH9*;P^D)NUPX=C+)<-UNG#Z%?.0W$"A8:4)Z:3_B-63E: Z_&*8_.P8X1^3Y9Q MG;KD[\:0_VY#_M^-(?_]"OG?$V:R[TKJJ*7>URM 6NI+57R:3HXX-@L_/:Y M8X#_OBJEICB.7C?)P]&WL<],:2,Q"_[A=/+X8;1[6N8;%)D+1 X3OD,",166 M-'"YS0P?4?81"PW@%;NO=:P85+8,-OR2FCP55)+O)31X50&I1F7:XG6B/UT> M15?0P+/.7;/=9#IULG[Z;=][PXD/=N#!W6 CHUQA]V/NF\B5U X&)H20VJN3$4G?%FE M$F0A7]1"6JDPAPZ;D\*.ISLG,]Q'> M@#13>,NL+/ _R[)JSD WKF.$%S"8'O1:YC'<-80II1+*8;!P'ZN: 74Q!T@: MLAV*'YLJ$VW]E?#<,V T%=?"8C4VMXXK+0@)1I*E,_)(6WNQC.UHZ]N;H:WW M5?DYT_6SZ+V]94=RRYYQ+U:0^/9:$@%.)TB!KQ98)HLO8=1ID,NIYB;(#FIH M4&CKC"\_T=MRN#UKK[)P@/ (]1\G'P^0B$=E/EEME+!K6M(+$@(.*._!E,C4 MU6A/)^6%%/-9T"+K//2ZTD77W;=08\'5DK3G+?(7*[N3CS6 R5<=2V1/Q4$Z\-G(FN@365CRA$B_C!_A1!;- MQ-,V&8$3';DX9_@O:Y0,HQ'EV2>+IVZ35/P;,G+PO5C&=AS\NYOAX#];C?J# M1D#JC5K2=$(TOEI1R?&5AA??-8E@=PPR46'D0PRA$^"U2='"NE[-?&3>5D56 M+T0/\;@')G"9P <&,$PS#J0\>*&;DL1N;/::^=RV3''M5)5MR1I+_:GH14$7 M !\DGFARA"K;&S?6MI[,WT9'YCV] <37C@P23CWZ*O>;[9P.IS\-:_:$MU2N MD&/C :,TJ1B\R0^_/S1A>/KM)H^=8^\XB+2)X&PN2?7-B_\/ M4$L#!!0 ( "E*FU:C9.*6SR$ $'V + 9F]R;3@M:RYH=&WM/6ES MVSBRW_DK\+0[N_:6[L..CVA+ENW$B:^QG&1FOZ0@$K(PH4@%I&QI?OWK!L!3 ME*_0CN0X-36V21P-H.]N-'?_.QW9Y)H)C[O.VW_7RM5_$^:8KL6=J[?_[O2Z M1T?__F_;V!WZT R:.M[;PM#WQ]N5RLW-3?FF47;%5:6VM;55F6*;@FJT/

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樫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end